IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i22p15172-d975578.html
   My bibliography  Save this article

Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma

Author

Listed:
  • Sunny Li-Yun Chang

    (Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan
    School of Medicine, China Medical University, Taichung 40402, Taiwan)

  • Po-Jen Yang

    (School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
    Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan)

  • Yen-You Lin

    (School of Medicine, China Medical University, Taichung 40402, Taiwan)

  • Ya-Jing Jiang

    (Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan)

  • Po-I Liu

    (Department of General Thoracic Surgery, Asia University Hospital, Taichung 41354, Taiwan)

  • Chang-Lun Huang

    (Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan
    Division of General Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan)

  • Shun-Fa Yang

    (Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
    Department of Medical Research, Chung Shan Medical University Hospital, Taichung 40201, Taiwan)

  • Chih-Hsin Tang

    (Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan
    School of Medicine, China Medical University, Taichung 40402, Taiwan
    Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan
    Department of Biotechnology, College of Health Science, Asia University, Taichung 41354, Taiwan)

Abstract

Lung adenocarcinoma (LUAD) is the most common histologic type of lung cancer. Mutations of the epidermal growth factor receptor (EGFR) gene are among the most common genetic alterations in LUAD and are the targets of EGFR tyrosine kinase inhibitors. The enzyme visfatin is involved in the generation of the oxidized form of nicotinamide adenine dinucleotide (NAD + ) and regulation of intracellular adenosine triphosphate (ATP), critical processes in cancer cell survival and growth. This study explored the relationship between visfatin single nucleotide polymorphisms (SNPs) with EGFR status and the clinicopathologic development of LUAD in a cohort of 277 Taiwanese men and women with LUAD. Allelic discrimination of four visfatin SNPs rs11977021, rs61330082, rs2110385 and rs4730153 was determined using a TaqMan Allelic Discrimination assay. We observed higher prevalence rates of advanced (T3/T4) tumors and distant metastases in EGFR wild-type patients carrying the rs11977021 CT + TT and rs61330082 GA + AA genotypes, respectively, compared with patients carrying the CC and GG genotypes. EGFR wild-type patients carrying the rs11977021 CT + TT genotypes were also more likely to develop severe (stage III/IV) malignancy compared with patients carrying the CC genotype. An analysis that included all patients found that the association persisted between the rs11977021 CT + TT and rs61330082 GA + AA genotypes and the development of T3/T4 tumors compared with patients carrying the rs11977021 CC and rs61330082 GG genotypes. In conclusion, these data indicate that visfatin SNPs may help to predict tumor staging in LUAD, especially in patients with EGFR wild-type status.

Suggested Citation

  • Sunny Li-Yun Chang & Po-Jen Yang & Yen-You Lin & Ya-Jing Jiang & Po-I Liu & Chang-Lun Huang & Shun-Fa Yang & Chih-Hsin Tang, 2022. "Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma," IJERPH, MDPI, vol. 19(22), pages 1-11, November.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:22:p:15172-:d:975578
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/22/15172/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/22/15172/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Jacqulyne P. Robichaux & Xiuning Le & R. S. K. Vijayan & J. Kevin Hicks & Simon Heeke & Yasir Y. Elamin & Heather Y. Lin & Hibiki Udagawa & Ferdinandos Skoulidis & Hai Tran & Susan Varghese & Junqin H, 2021. "Structure-based classification predicts drug response in EGFR-mutant NSCLC," Nature, Nature, vol. 597(7878), pages 732-737, September.
    2. Yao-Chen Wang & Shih-Ming Tsao & Yia-Ting Li & Chia-Yi Lee & Thomas Chang-Yao Tsao & Ming-Ju Hsieh & Shun-Fa Yang, 2021. "The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma," IJERPH, MDPI, vol. 18(6), pages 1-12, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Shen Zhao & Wu Zhuang & Baohui Han & Zhengbo Song & Wei Guo & Feng Luo & Lin Wu & Yi Hu & Huijuan Wang & Xiaorong Dong & Da Jiang & Mingxia Wang & Liyun Miao & Qian Wang & Junping Zhang & Zhenming Fu , 2023. "Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    2. Tikvah K. Hayes & Elisa Aquilanti & Nicole S. Persky & Xiaoping Yang & Erica E. Kim & Lisa Brenan & Amy B. Goodale & Douglas Alan & Ted Sharpe & Robert E. Shue & Lindsay Westlake & Lior Golomb & Brian, 2024. "Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    3. Lingzhi Hong & Muhammad Aminu & Shenduo Li & Xuetao Lu & Milena Petranovic & Maliazurina B. Saad & Pingjun Chen & Kang Qin & Susan Varghese & Waree Rinsurongkawong & Vadeerat Rinsurongkawong & Amy Spe, 2023. "Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    4. Ming-Hong Hsieh & Yi-Liang Wu & Thomas Chang-Yao Tsao & Yi-Wen Huang & Jian-Cheng Lin & Chia-Yi Lee & Ming-Ju Hsieh & Shun-Fa Yang, 2022. "Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients," IJERPH, MDPI, vol. 19(16), pages 1-9, August.
    5. Iris K. Alderwerelt van Rosenburgh & David M. Lu & Michael J. Grant & Steven E. Stayrook & Manali Phadke & Zenta Walther & Sarah B. Goldberg & Katerina Politi & Mark A. Lemmon & Kumar D. Ashtekar & Yu, 2022. "Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    6. Hui Deng & Qian Lei & Chengdi Wang & Zhoufeng Wang & Hai Chen & Gang Wang & Na Yang & Dan Huang & Quanwei Yu & Mengling Yao & Xue Xiao & Guonian Zhu & Cheng Cheng & Yangqian Li & Feng Li & Panwen Tian, 2022. "A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    7. Xiajing Gong & Meng Hu & Jinzhong Liu & Geoffrey Kim & James Xu & Amy McKee & Todd Palmby & R. Angelo Claro & Liang Zhao, 2022. "Decoding kinase-adverse event associations for small molecule kinase inhibitors," Nature Communications, Nature, vol. 13(1), pages 1-9, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:22:p:15172-:d:975578. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.